Updated:
STPharm
STPharm is a family office based in Pasadena with offices in San Diego, Seoul, and other cities, investing in biotech and pharmaceuticals.
STPharm
STPharm is a family office headquartered in Pasadena with additional offices in San Diego, Seoul, San Francisco, New York, Newport Beach, Atlanta, and Indianapolis. The firm's founding year and wealth origin are not publicly disclosed. The firm's investment activity centers on the biotech and pharmaceutical sectors, with a likely focus on therapeutic development, drug discovery, and healthcare services. STPharm appears to engage in direct investments and may co-invest with other life science-focused capital. Its geographic footprint suggests a strategy that bridges US and Asian markets. STPharm's team size and exact deployment scale are not public. The office network implies a decentralized operations model, with eight locations. No recent operational events were found in public sources. A structural differentiator is STPharm's broad geographic dispersal across multiple US cities and Seoul, which suggests a sourcing model that taps into regional biotech clusters. However, public information is thin, limiting a full assessment of its governance or mandate.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pasadena
Corporate office
Pasadena, CA, United States
Additional offices
San Diego · Seoul · San Francisco · New York · Newport Beach · Atlanta · Indianapolis
Sector focus
Frequently asked questions
What sectors does STPharm focus on?
STPharm's investment focus appears to be on biotech and pharmaceuticals, including therapeutic development and drug discovery. The firm's sector tags reflect this life sciences orientation, though public disclosures do not detail specific subsectors or stage preferences.
Does STPharm invest only in the US?
Based on its office locations, STPharm maintains a presence in both the United States and Asia, with an office in Seoul. This suggests a cross-border investment approach, likely tapping into US and Asian biotech markets.
How is STPharm structured?
STPharm is categorized as a family office, but its specific structure (single or multi-family) is not publicly documented. The firm operates from at least eight offices, indicating a dispersed operational model.
What is the wealth origin behind STPharm?
The wealth origin for STPharm is not publicly disclosed. Public records do not tie the family office to a specific individual or family fortune.
Does STPharm make direct investments or fund commitments?
Public information does not specify whether STPharm prefers direct investments, fund commitments, or co-investments. Given its family office label, direct deal activity is plausible, but no confirmations are available.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: